SG11201809297UA - Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients - Google Patents
Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patientsInfo
- Publication number
- SG11201809297UA SG11201809297UA SG11201809297UA SG11201809297UA SG11201809297UA SG 11201809297U A SG11201809297U A SG 11201809297UA SG 11201809297U A SG11201809297U A SG 11201809297UA SG 11201809297U A SG11201809297U A SG 11201809297UA SG 11201809297U A SG11201809297U A SG 11201809297UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- idalopirdine
- pct
- acetylcholinesterase inhibitor
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 DOI 010111110101111 0 111 01111101111111111111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/186686 Al 02 November 2017 (02.11.2017) W I PO I PCT (51) International Patent Classification: A61K 45/06 (2006.01) A61K 31/55 (2006.01) A61K 31/27 (2006.01) A61P 25/16 (2006.01) A61K 31/4045 (2006.01) A61P 25/28 (2006.01) A61K 31/445 (2006.01) (21) International Application Number: PCT/EP2017/059739 (22) International Filing Date: 25 April 2017 (25.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PA201600248 26 April 2016 (26.04.2016) DK (71) Applicant: H. LUNDBECK A/S [DK/DK]; Ottiliavej 9, 2500 Valby (DK). (72) Inventors: DE JONG, Inge, E, M; c/o H. LUNDBECK _ A/S Ottiliavej 9, 2500 Valby (DK). KUCINSKI, Aaron; 2402 Warner P1., Ann Arbor, MI 48104 (US). SARTER, — Martin; 5350 Arbor Meadow Lane, Ann Arbor, MI 48103 = (US). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (81) = _ CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = — = Designated States (unless otherwise indicated, for every (84) = = _ kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = Published: 1-1 , 1 — with international search report (Art. 21(3)) ' II L+ — before the expiration of the time limit for amending the , tD claims and to be republished in the event of receipt of GC ,tD amendments (Rule 48.2(h)) , tD GC 1-1 N (54) Title: USE OF AN ACETYLCHOLINESTERASE INHIBITOR AND IDALOPIRDINE FOR REDUCING FALLS IN Il PARKINSON'S DISEASE PATIENTS 0 ei (57) : The present invention relates to the use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in patients 0 suffering from a CNS disease, in particular patients with Parkin- son's disease, wherein balance, gait or movement is impaired.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600248 | 2016-04-26 | ||
| PCT/EP2017/059739 WO2017186686A1 (en) | 2016-04-26 | 2017-04-25 | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809297UA true SG11201809297UA (en) | 2018-11-29 |
Family
ID=58632402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809297UA SG11201809297UA (en) | 2016-04-26 | 2017-04-25 | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10383849B2 (en) |
| EP (1) | EP3448430B1 (en) |
| JP (1) | JP6992004B2 (en) |
| KR (1) | KR102473545B1 (en) |
| CN (1) | CN109069650A (en) |
| AU (1) | AU2017256623B2 (en) |
| BR (1) | BR112017026928B1 (en) |
| CA (1) | CA3020557C (en) |
| CL (1) | CL2018003013A1 (en) |
| CY (1) | CY1126138T1 (en) |
| DK (1) | DK3448430T3 (en) |
| ES (1) | ES2949288T3 (en) |
| FI (1) | FI3448430T3 (en) |
| HR (1) | HRP20230693T8 (en) |
| HU (1) | HUE062626T2 (en) |
| IL (1) | IL262546B (en) |
| LT (1) | LT3448430T (en) |
| MX (1) | MX2018013031A (en) |
| PL (1) | PL3448430T3 (en) |
| PT (1) | PT3448430T (en) |
| RS (1) | RS64307B1 (en) |
| RU (1) | RU2742173C2 (en) |
| SG (1) | SG11201809297UA (en) |
| SI (1) | SI3448430T1 (en) |
| TW (1) | TW201806621A (en) |
| WO (1) | WO2017186686A1 (en) |
| ZA (1) | ZA201806864B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111032038A (en) * | 2017-05-24 | 2020-04-17 | H.隆德贝克有限公司 | Pharmaceutical combination for the treatment of alzheimer's disease |
| JP2021515801A (en) * | 2017-12-22 | 2021-06-24 | ニューロセア，エルエルシー | Compositions and Methods for Treatments Related to Fall and Fall Frequency in Neurodegenerative Diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| ATE372768T1 (en) * | 2001-03-29 | 2007-09-15 | Lilly Co Eli | N-(2-ARYLETHYL) BENZYLAMINE AS A 5-HT6 RECEPTOR ANTAGONIST |
| ME01224B (en) * | 2005-04-04 | 2013-06-20 | Eisai R&D Man Co Ltd | Dihydropyridine compounds for neurodegenerative diseases and dementia |
| PE20071143A1 (en) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | PHARMACEUTICAL COMPOSITION INCLUDING AN ACETYLCHOLINESTERASE INHIBITOR AND A 5-HYDROXITRIPTAMINE-6 ANTAGONIST |
| MX2008015996A (en) * | 2006-06-23 | 2009-01-20 | Esteve Labor Dr | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity. |
| US9084742B2 (en) * | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| RU2393158C1 (en) * | 2008-10-06 | 2010-06-27 | Андрей Александрович Иващенко | SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-a]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS, METHODS OF PRODUCING AND USING SAID COMPOUNDS |
| JO3459B1 (en) * | 2012-09-09 | 2020-07-05 | H Lundbeck As | Pharmaceutical compositions for treating alzheimer's disease |
-
2017
- 2017-04-25 HU HUE17719255A patent/HUE062626T2/en unknown
- 2017-04-25 PL PL17719255.6T patent/PL3448430T3/en unknown
- 2017-04-25 FI FIEP17719255.6T patent/FI3448430T3/en active
- 2017-04-25 EP EP17719255.6A patent/EP3448430B1/en active Active
- 2017-04-25 WO PCT/EP2017/059739 patent/WO2017186686A1/en active Application Filing
- 2017-04-25 ES ES17719255T patent/ES2949288T3/en active Active
- 2017-04-25 KR KR1020187030934A patent/KR102473545B1/en active IP Right Grant
- 2017-04-25 SI SI201731371T patent/SI3448430T1/en unknown
- 2017-04-25 PT PT177192556T patent/PT3448430T/en unknown
- 2017-04-25 DK DK17719255.6T patent/DK3448430T3/en active
- 2017-04-25 MX MX2018013031A patent/MX2018013031A/en unknown
- 2017-04-25 HR HRP20230693TT patent/HRP20230693T8/en unknown
- 2017-04-25 RU RU2018135846A patent/RU2742173C2/en active
- 2017-04-25 JP JP2018555748A patent/JP6992004B2/en active Active
- 2017-04-25 CN CN201780025728.1A patent/CN109069650A/en active Pending
- 2017-04-25 BR BR112017026928-7A patent/BR112017026928B1/en active IP Right Grant
- 2017-04-25 CA CA3020557A patent/CA3020557C/en active Active
- 2017-04-25 TW TW106113760A patent/TW201806621A/en unknown
- 2017-04-25 AU AU2017256623A patent/AU2017256623B2/en active Active
- 2017-04-25 LT LTEPPCT/EP2017/059739T patent/LT3448430T/en unknown
- 2017-04-25 US US15/496,159 patent/US10383849B2/en active Active
- 2017-04-25 SG SG11201809297UA patent/SG11201809297UA/en unknown
- 2017-04-25 RS RS20230489A patent/RS64307B1/en unknown
-
2018
- 2018-10-15 ZA ZA2018/06864A patent/ZA201806864B/en unknown
- 2018-10-24 CL CL2018003013A patent/CL2018003013A1/en unknown
- 2018-10-24 IL IL262546A patent/IL262546B/en unknown
-
2023
- 2023-08-04 CY CY20231100395T patent/CY1126138T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201805061YA (en) | Crystalline form of gemcitabine | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |